Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (GB:0IJO)
LSE:0IJO
Holding GB:0IJO?
Track your performance easily
0IJO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.67 - $27.81
Previous Close$27.58
Volume1.75K
Average Volume (3M)1.53K
Market Cap
$7.87B
Enterprise Value$7.07B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$198.02M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Oct 30, 2024EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding285,251,725
10 Day Avg. Volume1,954
30 Day Avg. Volume1,532
Standard Deviation0.11
R-Squared0.02
Alpha0.00977
Financial Highlights & Ratios
Price to Book (P/B)3.63
Price to Sales (P/S)3.89
Price to Cash Flow (P/CF)15.80
P/FCF Ratio16.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda15.49
Forecast
1Y Price Target
$28.29Price Target Upside2.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Exelixis News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCabozantinib + Tecentriq elicited a statistically significant improvement in progression-free survival vs. a second novel hormonal therapy.
Financial PerformanceExelixis recorded diluted net income of $0.77 per share, higher than previously forecast.
Stock RepurchaseThe board of directors authorized the repurchase of up to an additional $500M of the company’s common stock.
Bears Say
Approval RisksApproval remains a risk and cabo's IP trial needs to be resolved for EXEL to get credit.
Clinical TrialsCONTACT-02 fails to show overall survival benefit in final analysis, ending filing pursuits in 1L RCC.
Regulatory PathEXEL will not pursue a regulatory path for cabo + nivo + ipi in 1L RCC due to the lack of an OS benefit at final analysis in the COSMIC-313 trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.37% Insiders
29.05% Mutual Funds
53.42% Other Institutional Investors
13.16% Public Companies and
Individual Investors
0IJO FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest share price was $18.67 and its highest was $27.80 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Oct 30, 2024 which is in 42 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 06, 2024. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.46.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.34.
How many shares outstanding does Exelixis have?
Exelixis has 285,251,740 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.77 in its last earnings report, beating expectations of $0.31. Following the earnings report the stock price went up 11.024%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 609M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.29 (2.56% Upside)
$28.29 (2.56% Upside)
Blogger Sentiment
Bullish
GB:0IJO Sentiment 94%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.54%
12-Months-Change
Fundamentals
Return on Equity
15.06%
Trailing 12-Months
Asset Growth
-11.75%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
0IJO Company Deck
---
0IJO Earnings Call
Q2 2024
0:00 / 0:00
---
0IJO Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
0IJO Stock 12 Month Forecast
Average Price Target
$28.29
▲(2.56% Upside)
Technical Analysis
Best Analysts Covering 0IJO
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+23.57%
reiterated a buy rating 15 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.57% per trade.
---